Skip to main content

01.02.2024 | Originalien

Impact of gout on cardiovascular disease mortality: a meta-analysis

verfasst von: Jielin Yuan, Zhitao Xie, Bo Pan, Jingchang Zhang

Erschienen in: Zeitschrift für Rheumatologie

Einloggen, um Zugang zu erhalten

Abstract

Background

Several epidemiological studies have suggested that gout patients have a higher risk of cardiovascular disease mortality than healthy people. In contrast, the association between gout and cardiovascular disease (CVD) mortality was not obvious in other studies. In the present study, we aimed to investigate the relative risk for CVD mortality in gout patients in comparison to healthy controls.

Methods

Literature published before March 2023 was searched in Google Scholar, PubMed, and the Web of Science. We summarized the impact of gout on CVD mortality with a meta-analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) regarding the impact of gout on CVD mortality were summarized with STATA 12.0 software.

Results

Compared to individuals without gout, those with gout had higher mortality risks for CVD during follow-up, with a random effects model showing a risk of 1.30 (95% CI 1.15 to 1.48, p < 0.001; p-value for Cochran Q test < 0.001, I2 = 95.9%). Similarly, subjects with gout had a mortality risk of 1.28 (95% CI 1.12 to 1.46, p < 0.001; p-value for Cochran Q test = 0.050, I2 = 50.2%) for coronary heart disease (CHD) mortality during follow-up using the same statistical model. Furthermore, using a fixed effects model, individuals with gout had a mortality risk of 1.13 (95% CI 1.00 to 1.27, p = 0.049; p-value for Cochran Q test = 0.494, I2 = 0.0%) for myocardial infarction (MI) mortality during follow-up.

Conclusion

In conclusion, this meta-analysis provides evidence supporting a markedly increased mortality risk from CVD and CHD as well as MI in patients with gout relative to reference subjects without gout.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Scinicariello F, Buser MC, Balluz L, Gehle K, Murray HE, Abadin HG et al (2020) Perfluoroalkyl acids, hyperuricemia and gout in adults: analyses of NHANES 2009–2014. Chemosphere 259:127446ADSPubMedPubMedCentralCrossRef Scinicariello F, Buser MC, Balluz L, Gehle K, Murray HE, Abadin HG et al (2020) Perfluoroalkyl acids, hyperuricemia and gout in adults: analyses of NHANES 2009–2014. Chemosphere 259:127446ADSPubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F et al (2019) Gout. Nat Rev Dis Primers 5(1):69PubMedCrossRef Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F et al (2019) Gout. Nat Rev Dis Primers 5(1):69PubMedCrossRef
3.
Zurück zum Zitat Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J et al (2020) 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79(1):31–38PubMedCrossRef Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J et al (2020) 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79(1):31–38PubMedCrossRef
4.
Zurück zum Zitat Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50(3s):S11–s6PubMedCrossRef Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50(3s):S11–s6PubMedCrossRef
5.
Zurück zum Zitat Shen X, Wang C, Liang N, Liu Z, Li X, Zhu ZJ et al (2021) Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol 73(9):1738–1748PubMedCrossRef Shen X, Wang C, Liang N, Liu Z, Li X, Zhu ZJ et al (2021) Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol 73(9):1738–1748PubMedCrossRef
6.
Zurück zum Zitat Abhishek A, Roddy E, Doherty M (2017) Gout—a guide for the general and acute physicians. Clin Med 17(1):54–59CrossRef Abhishek A, Roddy E, Doherty M (2017) Gout—a guide for the general and acute physicians. Clin Med 17(1):54–59CrossRef
7.
Zurück zum Zitat Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 23(2):192–202PubMedPubMedCentralCrossRef Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 23(2):192–202PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Chang DY, Wang JW, Chen M, Zhang LX, Zhao MH (2021) Association between serum uric acid level and mortality in China. Chin Med J 134(17):2073–2080PubMedPubMedCentralCrossRef Chang DY, Wang JW, Chen M, Zhang LX, Zhao MH (2021) Association between serum uric acid level and mortality in China. Chin Med J 134(17):2073–2080PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Freilich M, Arredondo A, Zonnoor SL, McFarlane IM (2022) Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus 14(3):e23582PubMedPubMedCentral Freilich M, Arredondo A, Zonnoor SL, McFarlane IM (2022) Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus 14(3):e23582PubMedPubMedCentral
10.
11.
Zurück zum Zitat Dehlin M, Sandström TZ, Incident Gout JLT (2022) Risk of death and cause-specific mortality in western Sweden: a prospective, controlled inception cohort study. Front Med 9:802856CrossRef Dehlin M, Sandström TZ, Incident Gout JLT (2022) Risk of death and cause-specific mortality in western Sweden: a prospective, controlled inception cohort study. Front Med 9:802856CrossRef
12.
Zurück zum Zitat Vargas-Santos AB, Neogi T, da Rocha Castelar-Pinheiro G, Kapetanovic MC, Turkiewicz A (2019) Cause-specific mortality in gout: novel findings of elevated risk of non-cardiovascular-related deaths. Arthritis Rheumatol 71(11):1935–1942PubMedPubMedCentralCrossRef Vargas-Santos AB, Neogi T, da Rocha Castelar-Pinheiro G, Kapetanovic MC, Turkiewicz A (2019) Cause-specific mortality in gout: novel findings of elevated risk of non-cardiovascular-related deaths. Arthritis Rheumatol 71(11):1935–1942PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Singh TP, Wong S, Quigley F, Jenkins J, Golledge J (2020) Association of gout with major adverse cardiovascular events and all-cause mortality in patients with peripheral artery disease. Atherosclerosis 312:23–27PubMedCrossRef Singh TP, Wong S, Quigley F, Jenkins J, Golledge J (2020) Association of gout with major adverse cardiovascular events and all-cause mortality in patients with peripheral artery disease. Atherosclerosis 312:23–27PubMedCrossRef
14.
Zurück zum Zitat Pagidipati NJ, Hess CN, Clare RM, Akerblom A, Tricoci P, Wojdyla D et al (2017) An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. Am Heart Hosp J 187:53–61CrossRef Pagidipati NJ, Hess CN, Clare RM, Akerblom A, Tricoci P, Wojdyla D et al (2017) An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. Am Heart Hosp J 187:53–61CrossRef
15.
Zurück zum Zitat Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16(7):380–390PubMedCrossRef Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16(7):380–390PubMedCrossRef
16.
17.
Zurück zum Zitat Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559–1573PubMedCrossRef Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559–1573PubMedCrossRef
18.
Zurück zum Zitat Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63(10):1426–1434PubMedCrossRef Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63(10):1426–1434PubMedCrossRef
19.
Zurück zum Zitat Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthritis Rheum 54(8):2688–2696PubMedCrossRef Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthritis Rheum 54(8):2688–2696PubMedCrossRef
20.
Zurück zum Zitat Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900PubMedCrossRef Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900PubMedCrossRef
21.
Zurück zum Zitat Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH (2008) Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 168(10):1104–1110PubMedCrossRef Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH (2008) Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 168(10):1104–1110PubMedCrossRef
22.
Zurück zum Zitat De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK (2010) Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 69(6):1162–1164PubMedCrossRef De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK (2010) Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 69(6):1162–1164PubMedCrossRef
23.
Zurück zum Zitat Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS et al (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 49(1):141–146PubMedCrossRef Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS et al (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 49(1):141–146PubMedCrossRef
24.
Zurück zum Zitat Kok VC, Horng JT, Lin HL, Chen YC, Chen YJ, Cheng KF (2012) Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord 12:108PubMedPubMedCentralCrossRef Kok VC, Horng JT, Lin HL, Chen YC, Chen YJ, Cheng KF (2012) Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord 12:108PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O (2012) Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 14(1):R10PubMedPubMedCentralCrossRef Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O (2012) Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 14(1):R10PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP (2012) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 71(6):924–928PubMedCrossRef Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP (2012) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 71(6):924–928PubMedCrossRef
27.
Zurück zum Zitat Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. Qjm 106(7):647–658PubMedCrossRef Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. Qjm 106(7):647–658PubMedCrossRef
28.
Zurück zum Zitat Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ et al (2015) Effect of Urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol 42(9):1694–1701PubMedCrossRef Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ et al (2015) Effect of Urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol 42(9):1694–1701PubMedCrossRef
29.
Zurück zum Zitat Pagidipati NJ, Clare RM, Keenan RT, Chiswell K, Roe MT, Hess CN (2018) Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease. J Am Heart Assoc 7(16):e9328PubMedPubMedCentralCrossRef Pagidipati NJ, Clare RM, Keenan RT, Chiswell K, Roe MT, Hess CN (2018) Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease. J Am Heart Assoc 7(16):e9328PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 22(3):335–343PubMedPubMedCentralCrossRef Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 22(3):335–343PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Lottmann K, Chen X, Schädlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 14(2):195–203PubMedPubMedCentralCrossRef Lottmann K, Chen X, Schädlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 14(2):195–203PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Disveld IJM, Fransen J, Rongen GA, Kienhorst LBE, Zoakman S, Janssens H et al (2018) Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease. J Rheumatol 45(6):858–863PubMedCrossRef Disveld IJM, Fransen J, Rongen GA, Kienhorst LBE, Zoakman S, Janssens H et al (2018) Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease. J Rheumatol 45(6):858–863PubMedCrossRef
33.
Zurück zum Zitat Huang WS, Lin CL, Tsai CH, Chang KH (2020) Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. J Investig Med 68(5):972–979PubMedPubMedCentralCrossRef Huang WS, Lin CL, Tsai CH, Chang KH (2020) Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. J Investig Med 68(5):972–979PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Chuang TJ, Wang YH, Wei JC, Yeh CJ (2021) Anti-gout medications and risk of cardiovascular disease: a nested case-control study. Front Med 8:739680CrossRef Chuang TJ, Wang YH, Wei JC, Yeh CJ (2021) Anti-gout medications and risk of cardiovascular disease: a nested case-control study. Front Med 8:739680CrossRef
35.
Zurück zum Zitat Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71(4):600–607PubMedPubMedCentralCrossRef Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 71(4):600–607PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Kok VC, Horng JT, Chang WS, Hong YF, Chang TH (2014) Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PloS One 9(6):e99102ADSPubMedPubMedCentralCrossRef Kok VC, Horng JT, Chang WS, Hong YF, Chang TH (2014) Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PloS One 9(6):e99102ADSPubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M (2003) Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 20(4):413–416PubMedCrossRef Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M (2003) Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 20(4):413–416PubMedCrossRef
38.
Zurück zum Zitat Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A et al (2012) Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J 126(1368):53–64PubMed Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A et al (2012) Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J 126(1368):53–64PubMed
39.
Zurück zum Zitat Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125(7):679–687.e1PubMedCrossRef Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125(7):679–687.e1PubMedCrossRef
41.
Zurück zum Zitat Zhang Y, Peloquin CE, Dubreuil M, Roddy E, Lu N, Neogi T et al (2015) Sleep apnea and the risk of incident gout: a population-based, body mass index-matched cohort study. Arthritis Rheumatol 67(12):3298–3302PubMedPubMedCentralCrossRef Zhang Y, Peloquin CE, Dubreuil M, Roddy E, Lu N, Neogi T et al (2015) Sleep apnea and the risk of incident gout: a population-based, body mass index-matched cohort study. Arthritis Rheumatol 67(12):3298–3302PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Disveld IJM, Zoakman S, Jansen T, Rongen GA, Kienhorst LBE, Janssens H et al (2019) Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol 38(5):1385–1391PubMedCrossRef Disveld IJM, Zoakman S, Jansen T, Rongen GA, Kienhorst LBE, Janssens H et al (2019) Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol 38(5):1385–1391PubMedCrossRef
43.
Zurück zum Zitat Ould Setti M, Voutilainen A, Tuomainen TP (2021) Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. Epidemiol Health 43:e2021001PubMedCrossRef Ould Setti M, Voutilainen A, Tuomainen TP (2021) Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. Epidemiol Health 43:e2021001PubMedCrossRef
44.
Zurück zum Zitat Li F, Wang Z, Li S, Liu W, Li Y, Jiang C et al (2023) Association of body fat distribution with all-cause and cardiovascular mortality in US adults: a secondary analysis using NHANES. BMJ Open 13(11):e72752PubMedPubMedCentralCrossRef Li F, Wang Z, Li S, Liu W, Li Y, Jiang C et al (2023) Association of body fat distribution with all-cause and cardiovascular mortality in US adults: a secondary analysis using NHANES. BMJ Open 13(11):e72752PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Tverdal A, Selmer R, Thelle DS (2023) Smoking history and all-cause, ischaemic heart disease and lung cancer mortality: follow-up study of 358 551 men and women aged 40–43 years. Tob Control Tverdal A, Selmer R, Thelle DS (2023) Smoking history and all-cause, ischaemic heart disease and lung cancer mortality: follow-up study of 358 551 men and women aged 40–43 years. Tob Control
46.
Zurück zum Zitat Kimura Y, Tsukui D, Kono H (2021) Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci 22:22CrossRef Kimura Y, Tsukui D, Kono H (2021) Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci 22:22CrossRef
47.
Zurück zum Zitat Cai W, Duan XM, Liu Y, Yu J, Tang YL, Liu ZL et al (2017) Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. Biomed Res Int 2017:4391920PubMedPubMedCentralCrossRef Cai W, Duan XM, Liu Y, Yu J, Tang YL, Liu ZL et al (2017) Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. Biomed Res Int 2017:4391920PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Rock KL, Kataoka H, Lai JJ (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 9(1):13–23PubMedCrossRef Rock KL, Kataoka H, Lai JJ (2013) Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 9(1):13–23PubMedCrossRef
49.
Zurück zum Zitat Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963PubMedCrossRef
50.
Zurück zum Zitat Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104(16):1887–1893PubMedCrossRef Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U et al (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104(16):1887–1893PubMedCrossRef
Metadaten
Titel
Impact of gout on cardiovascular disease mortality: a meta-analysis
verfasst von
Jielin Yuan
Zhitao Xie
Bo Pan
Jingchang Zhang
Publikationsdatum
01.02.2024
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-024-01479-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.